Hatch-Waxman and Biosimilars Veteran Jay R. Deshmukh Rejoins Kasowitz’s Intellectual Property Group
Jay R. Deshmukh has rejoined Kasowitz as a partner in the firm’s New York office. Mr. Deshmukh brings over 25 years of Hatch-Waxman Act and BPCIA (Biosimilars) experience to the firm’s Intellectual Property Litigation group.
Mr. Deshmukh’s practice focuses on complex intellectual property and patent infringement cases that include major Hatch-Waxman and Biosimilars litigations. He regularly counsels international generic drug makers on product launches and defends clients against suits from brand-name manufacturers. Mr. Deshmukh serves as settlement and Food and Drug Administration (FDA) counsel for smaller generic pharmaceutical companies, where he has a successful track record prevailing in exclusivity matters against the Office of the Chief Counsel of the FDA. He also has extensive experience working with the Federal Trade Commission.
Prior to rejoining Kasowitz, Jay was a partner at an international law firm. He also served as Senior Vice President of Global IP at Ranbaxy Laboratories, an international generic pharmaceutical company, where he was responsible for the creation of the company’s global intellectual property department.
Kasowitz’s Intellectual Property Litigation group has extensive experience in all aspects of patent, trademark, trade secret, false advertising, and related antitrust and unfair competition litigation, representing some of the world’s largest pharmaceutical and technology companies as both plaintiff and defendant.